Abstract
CD4+ T cell activation promotes the pathogenic process of systemic lupus erythematosus (SLE). T cell receptor (TCR) complex are highly core fucosylated glycoproteins, which play important roles in T cell activation. In this study, we found that the core fucosylation of CD4+ T cells was significantly increased in SLE patients. Loss of core fucosyltransferase (Fut8), the sole enzyme for catalyzing the core fucosylation of N-glycan, significantly reduced CD4+ T cell activation and ameliorated the experimental autoimmune encephalomyelitis-induced syndrome in Fut8−/− mice. T cell activation with OVA323–339 loaded major histocompatibility complex II (pMHC-II) on B cell was dramatically attenuated in Fut8−/−OT-II CD4+ T cells compared with Fut8+/+OT-II CD4+ T cells. Moreover, the phosphorylation of ZAP-70 was significantly reduced in Fut8+/+OT-II CD4+ T cells by the treatment of fucosidase. Our results suggest that core fucosylation is required for efficient TCR–pMHC-II contacts in CD4+ T cell activation, and hyper core fucosylation may serve as a potential novel biomarker in the sera from SLE patients.
Keywords: core fucosylation, T cell receptor, T cell activation, systemic lupus erythematosus, T–B cell interaction
Introduction
Systemic lupus erythematosus (SLE) is a severe autoimmune disease that characterized by the production of autoantibodies and the subsequent inflammatory disorders (1). Although the pathogenesis is not completely understood, the activation of CD4+ T cells seems plays an essential role in the onset and development of SLE (2). Appropriate CD4+ T cell activation is crucially important for adaptive immune responses and autoimmunity, but hyper-activation of these cells results in autoimmune diseases. T cell recognition of peptide-loaded major histocompatibility complex II (pMHC-II) on the antigen-presenting cells (APCs) by T cell receptors (TCRs) is the most important checkpoint for CD4+ T cell activation (3). During antigen recognition, the CD4 coreceptor binds to the non-polymorphic surfaces of the membrane-proximal domains of the same pMHCs, which results in a marked increase in the sensitivity of T cells to pMHCs on APC. When adequate agonistic TCR signaling creates a favorable microenvironment for binding, CD28-B7 molecules provide costimulatory lower the thresholds for TCRs triggering and activation. The signaling through TCR induces a conformational change in leukocyte function-associated antigen-1, which greatly increases its affinity for intercellular adhesion molecule 1 and contributes to immune synapse formation T cells and APC (4, 5).
Glycosylation plays a regulatory and often pivotal role in T cell activation (6–10). Several studies have reported that glycosylation could contribute to higher activation thresholds of T cells. For instance, β1,6N-acetylglucosaminyltransferase V (Mgat5) deficiency mediates lower T lymphocyte activation thresholds, and subsequently improves T cell activity in vitro and results in autoimmune disease in vivo (11, 12). Deletion of sialyltransferase ST3Gal-1 increase the sensitivity of TCRs to low-affinity ligands in CD8+ T cells (13). Fucosyltransferase 1 transgenic mice show increased TCR signaling and apoptosis that results in thymocyte maturation arrest (14). Notably, reduced N-glycosylation of TCR chains can improve functional avidity and recognition by T cells (15) suggesting that the glycosylation of TCR has a unique role in the regulation of T cell activation.
T cell receptors are heavily core-fucosylated glycoproteins. The core fucosylation of protein is catalyzed by core fucosyltransferase (Fut8), which transfers fucose residue from GDP-fucose to the innermost N-acetylglucosamine (GlcNAc) residue of N-linked glycans via an α1,6 linkage in the Golgi apparatus of mammalians (Figure S1 in Supplementary Material). Fut8-mediated core fucosylation is an important post-translational process (16), which regulates protein conformation, stability, and functional expression. Studies have shown that the N-glycans at Asn70 [GlcNAc(α1,6Fuc)-β1,4GlcNAc: (A2G2F)], Asn185 (A2G2F), and Asn203 in the α chain (Cα) and Asn236 in the β chain (Cβ) extend from the surface of TCR on Drosophila melanogaster cells (6, 17). Interestingly, they found that the Cα and Cβ of TCR were connected by the hydrogen bonds of the core fucose residue from Asn185α (A2G2F) to side chains of Glu181β and Ser182β (6, 17), suggesting a crucial role of core fucosylation on the conformation of TCR. However, to the best of our knowledge, none of the previous studies had addressed the regulatory role of TCR core fucosylation on CD4+ T cell activation.
B cells play a role in evoking T cell responses by functioning as APCs, and the presentation of peptide by MHC-II on the B cells initiates T cell activation (18). Therefore, it is reasonable to anticipate that the core fucosylation has significant functional implications in T–B cell interaction, and thus affect the CD4+ T cell activation. In this study, we provide the first confirmation that SLE patients exhibited hyper core fucosylation on CD4+ T cells, which significantly enhanced the activation of their CD4+ T cells. Knockout of Fut8 gene resulted in attenuated T–B cell interaction via TCR–pMHC and the consequential reduced CD4+ T cell activation. Our data suggest that the core fucosylation may serve as a potential novel biomarker with promising clinical and therapeutic implications in SLE patients.
Materials and Methods
Mice
Fut8−/− mice were generated as previously described (19), and homozygous wild-type (Fut8+/+) and Fut8−/− mice on the C57BL/6 background were obtained by crossing heterozygous Fut8+/− mice (C57BL/6). OT-II (Jackson Laboratory) is a C57BL/6 TCR transgenic strain, expressing a receptor specific for peptide OVA323–339. Fut8+/+OT-II mice and Fut8−/−OT-II mice were generated by crossing heterozygous Fut8+/−OT-II mice. Mice were maintained in the specific pathogen-free laboratory animal facility of Dalian Medical University. All animal work was approved by the Ethics Committee at the Dalian Medical University.
Patients
Serum samples were collected from a total of 17 SLE patients (14 women, 3 men; mean age, 49 years; range, 18–67 years) with and healthy controls (12 women, 12 men; mean age, 18–48 years) (Table S1 in Supplementary Material). The diagnosis of underlying disease was made based on clinical manifestation, serology, imaging, and/or histopathology. These participants were Chinese, recruited at Dalian municipal central hospital. The anti-nuclear antibodies (ANA) titers of AD patients were detected with using Anti-nuclear Antibodies IgG Kit (EUROIMMUN, Germany). The Ethics Committee at the hospital approved the study protocol.
Antibodies
Anti-CD16/32 (2.4G2), anti-CD3(145-2c11), anti-CD28 (37.51), FITC-anti-MHC II (M5/114.15.2), FITC-anti-CD69 (H1.2F3), PE-labeled anti-CD4 (GK1.5), APC-labeled anti-CD8 (53-6.7), biotin-labeled anti-TCRβ (H57-597), and PE-Cy5-labeled anti-TCRβ (H57-597) were obtained from e-Bioscience; anti-GAPDH, horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG and HRP-conjugated donkey anti-human IgG were obtained from proteintech; additional biotin-conjugated lens culinaris agglutinin (LCA) were purchased from Vector; anti-TCRαβ (ab25336), anti-pZAP70 (ab194800), anti-ZAP70 (ab32410), Natural streptavidin protein (FITC) (ab136201), and streptavidin (HRP) (ab7403) were purchased from Abcam.
Histological Analysis
Formalin-fixed tissue samples were paraffin-embedded and sections were analyzed by hematoxylin–eosin (H&E) staining. The sections were stained with biotin-conjugated LCA. Briefly, sections were deparaffinized three times in xylene and hydrated through a 100, 90, 80, and 70% ethanol to phosphate-buffered saline (PBS). To quench the endogenous peroxidase activity, slides were incubated with 3% H2O2 for 30 min. Then, the slides were incubated with biotin-conjugated LCA, and washed three times with PBS. The slides probed with HRP–streptavidin for 30 min, and visualized with 3,3′-diaminobenzidine. The intensity of LCA-positive staining in the spleen was analyzed by integrated optical density using Image-Pro® Plus software (version 6.0; Media Cybernetics, USA).
Cell Lysate
Cells were solubilized in lysis buffer [Tris–HCl (50 mM), 1% Triton X-100, 10% glycerol, phenylmethylsulfonylfluoride (100 µM), leupeptin (5 µg/mL), aprotinin (1 µg/mL), NaF (100 mM), 150 mM NaCl, 2 mM EDTA, and sodium orthovanadate (1 mM)] for 15 min at 4°C. Cell lysate was centrifuged at 20,000 × g for 10 min at 4°C, and the supernatant was subjected to immunoprecipitation or Western blot, as indicated below.
Fut8 Enzyme Activity Assay
The Fut8 enzyme activity was measured by using the previous method (20). Five micrograms cell lysates as the enzyme source were added to the assay buffer (200 mM MES, 1% Triton X-100) supplemented with donor (500 µM GDP-L-fucose) and substrate [50 µM GnGn-Asn-4-(2-pyridylamine) butylamine (PABA)]. The mixture was incubated at 37°C for 8 h, and the reaction was stopped by heating at 100°C for 5 min. The reactive solution was then centrifuged at 12,000 × g for 10 min, and 10 µL of the reaction products were subjected to high-performance liquid chromatography (HPLC) with a Fluorescent detector (Waters Corporation, USA). The excitation and emission wavelengths are 320 and 400 nm, respectively.
PCR Array
Total RNAs were extracted from Fut8+/+ SPLs and Fut8−/− SPLs with TRIzol reagent (Takara Bio). Mouse T Cell and B Cell Activation PCR Array (SA Biosciences) was carried out according to the protocol of the manufacturer. The difference of gene expression between Fut8+/+ SPLs and Fut8−/− SPLs was calculated.
Animal Immunization
Mouse was immunized by subcutaneous injection with 200 µg OVA mixed with an equal volume of complete Freund’s adjuvant (CFA) (Sigma). Two weeks later, mice were immunized with 200 µg OVA by subcutaneous injection. Mice sera were collected at 0, 7, and 14 days post-immunization.
Enzyme-Linked Immunosorbent Assay (ELISA)
The concentrations of IL-2 analyzed using mouse IL-2 ELISA kits (Boster Biological Engineering, Wuhan, China), according to the manufacturer’s instructions. The concentrations of IL-2 were calculated according to a standard curve prepared using samples of known concentration. The absorbance was measured at a test wavelength of 450 nm with a microplate reader.
The immunoglobulin isotypes were measured by mouse mAb isotyping reagents (Sigma).
Cell Proliferation Assay
The growth rate of cells was measured using MTT assay. CD4+ T cells (1 × 106) were cultured in 96-well culture plate with anti-CD3ε (2 µg/mL) and anti-CD28 mAbs (1 µg/mL). After 48 h of incubation, each well was added 10 µL of MTT solution, and then the absorbance was analyzed by a microplate reader (Thermo Multiskan Ascent, Finland) at 570 nm.
In addition, T cell proliferation with the OVA323–339-loaded B cells was analyzed by carboxyfluorescein diacetatesuccinimidyl ester (CFSE, Sigma) dilution methods. CD4+ T cells (1 × 106) were purified, and then labeled with 5 µM CFSE in PBS for 8 min at room temperature and coincubate with OVA323–339 loaded Fut8+/+ OT-II B cells (1 × 106) for 48 h, and then analyzed by flow cytometric analysis.
Western Blot and Lectin Blot Analysis
Protein samples were electrophoresed on 10% polyacrylamide gels. After electrophoresis at 240 mA for 30 min, proteins were transferred to PVDF membranes. Membranes were blocked in 5% BSA in TBS-T (10 mM Tris–HCl, 150 mM NaCl, and 0.1% Tween 20) at room temperature for 1 h, and then incubated with the biotin-labeled LCA, which preferentially recognizes the core fucose, or primary Abs in 1% BSA in TBS-T overnight at 4°C. After washing, the membranes were covered with the HRP-conjugated streptavidin or HRP-labeled secondary Abs at room temperature for 1 h, and visualized with an ECL system (Amersham).
Immunoprecipitation
Cell extracts (500 µg) were mixed with 20 µL of Protein G-Sepharose (50%) and corresponding Abs, and then incubated at 4°C overnight with continuous rotation. After washing three times in lysis buffer, the pull downed samples were boiled for 5 min in Laemmli sample buffer with or without 2-mercaptoethanol.
T–B Cell Conjugate Formation
Conjugate formation between T cells and B cells were carried out as described previously with slight modification (21). T cells and 1 µg/mL OVA323–339 (NH2-ISQAVHAAHAEINEAGR-COOH)-pulsed B cells were mixed at a 1:1 ratio and a quick centrifugation to initiate cell–cell contact. To observe conjugate formation, B cells and T cells were labeled with MHC-II-FITC and TCRβ-PE-Cy5 before mixing. T–B cell conjugates were then analyzed by flow cytometry to determine the percentage of T–B cells that had both TCRβ-PE-Cy5 and MHC-II-FITC positive staining.
Remove of Core Fucose on Surface of T Cells
Purified CD4+ T cells (4 × 106) were treated with 100 mU Glyko® α(1-2,3,4,6) Bovine Kidney Fucosidase (GKX-5006, Prozyme), incubate 3 h at 37°C in the reaction buffer. The enzyme reaction was terminated by centrifuging at 2,500 × g for 5 min and the cells were collected.
Confocal Microscopy
Conjugate formation between T cells and B cells were carried out as described previously with slight modification (21). T cells and 1 µg/mL OVA323–339 pulsed B cells were mixed at a 1:1 ratio and a quick centrifugation to initiate cell–cell contact. Cell–cell conjugates were subsequently transferred to poly-d-lysine coated coverslips and incubated at 37°C for 30 min. Cells were fixed with 4% PFA for 20 min, and then blocked with 5% BSA and anti-CD16/CD32 (2.4G2) mAb for 30 min. After washing, cells were stained with anti-MHC-II Ab for 1 h. All images were taken using a spinning disk confocal microscope (Leica).
MACS Magnetic Cell Sorting
Single splenic cell suspensions were prepared by first grinding the tissues and then by passage through 30-µm nylon mesh. Red blood cells were lysed by incubation with 0.14 M NH4Cl and 20 mM Tris (pH7.4) for 3 min at room temperature. After the lysis of red blood cells, CD4+ T cells and B cells were positively isolated with anti-CD4 Ab and anti-CD45R Ab-conjugated magnetic beads (Miltenyi Biotec). The purified cell populations were detected by fluorescence activated cell sorting analysis.
Flow Cytometric Analysis (FACS)
Cells were isolated from tissue and incubated with an anti-CD16/CD32 (2.4G2) mAb to block Fcγ receptors. The cells were stained on ice for 15 min with several combinations of mAbs, as indicated in the figure legends. Flow cytometry was performed on a FACS-Calibur (Becton Dickinson, Mountain View, CA, USA) and analyzed using FlowJo software (Tree Star).
Induction of Experimental Autoimmune Encephalomyelitis (EAE)
For EAE induction, Fut8+/+ and Fut8−/− mice were subcutaneously injected with 100 µg of myelin oligodendrocyte glycoprotein peptides (MOG35–55) emulsified in CFA. Then, mice were injected intraperitoneally with 200 µg pertussis toxin (PTX) (List Biological Laboratories) on 0, 1, and 2 days. Clinical assessment of EAE was performed according to the following scale: 0, no disease; 1, limp tail; 2, hind-limb weakness; 3, partial hind-limb paralysis; 4, complete paralysis of hind-limbs; and 5, moribund state.
Statistical Analysis
Student’s t-test was used for statistical analysis. Data are presented as mean values ± SEM, or as mean values ± SD. A probability value of p < 0.05 was considered significant. *p < 0.05, **p < 0.01, ***p < 0.001.
Results
Core Fucosylation Is Significantly Upregulated in the Sera and CD4+ T Cells of SLE Patients
Higher circulating levels of ANA were detected in sera from SLE patients. In this study, we found that core fucosylation was dramatically increased in the sera from patients with SLE, as evidenced by LCA, which preferentially recognizes the core fucose structure (22) (p < 0.001) (Figures 1A,B). The expression of IgGs was also upregulated in sera of the SLE patients (p < 0.05) (Figure 1B). These observations pinpoint the contribution of hyper core fucosylation to SLE severity and pathogenesis.
The hyperactivity of B cells in SLE is T cell dependent, and CD4+ T cell activation plays a crucial role in SLE pathogenesis (23). We found that the percentage of CD4+ T cells in the peripheral blood of SLE patients is similar to those of healthy control (Figure 1C). However, the percentage of CD4+CD69+ T cells was significantly increased in the SLE (n = 17) (Figure 1D). Moreover, the enzyme activity of Fut8 was dramatically increased in the CD4+ T cells isolated from the SLE patients (Figures 1E,F), indicated that increased core fucosylation in SLE patients correlates with CD4+ T cell activation.
Lack of Core Fucosylation Ameliorated EAE Symptoms with Reduced CD4+ T Cell Activation
Wild-type (Fut8+/+) and Fut8−/− mice were generated previously (19). Histological analyses of the splenic architecture of Fut8+/+ and Fut8−/− mice were unremarkable in H&E staining. The Fut8 products, core-fucosylated N-glycans, are ubiquitously expressed in the Fut8+/+ spleen, as confirmed by LCA (Figure 2A), while those were abolished in Fut8−/− spleens. LCA blot analysis also confirmed the knockout of Fut8 expression in the whole cell lysates of Fut8−/− SPLs (Figure 2B). The FUT8 enzymatic activity was not detected in the Fut8−/− SPLs using HPLC analysis (Figure 2C).
Experimental autoimmune encephalomyelitis is an activated CD4+ T cell-mediated autoimmune disease model. Peptides (MOG35–55) and PTX could induce the migration of activated T cells through the blood–brain barrier and caused several neurologic symptoms. To determine the association between core fucosylation and the activation of CD4+ T cells, EAE models were established using Fut8+/+ and Fut8−/− mice. EAE is actively induced but appear more quickly upon adoptive transfer of activated MOG35–55-specific T cells in Fut8+/+ mice (Figure 2D; Video S1 in Supplementary Material), while Fut8−/− mice showed slight EAE symptoms (Figure 2D; Video S2 in Supplementary Material). The body weights of Fut8+/+ mice were significantly reduced, but no change was found in Fut8−/− mice during EAE induction (Figure 2D). In addition, the proliferation of CD4+ T cells was significantly decreased in Fut8−/− EAE mice. Moreover, the proliferation of CD4+ T cells with MOG35–55-loaded B cells was remarkably reduced by de-core fucosylation (Figure 2E).
Lack of Core Fucosylation Suppressed the IgG Class-Switching by Impaired CD4+ T Cell Activation
Flow cytometry analysis revealed that, although Fut8−/− mice contained normal proportions of CD4+ and CD8+ T cell populations in the spleen (Figures 3A,B), they were markedly reduced after OVA immunization contrast with the Fut8+/+ mice (Figures 3A,B). Immunoglobulin class-switching is a biological mechanism that changes a mature B cell’s production of antibody via its B cell receptor from one class to another. For example, from an isotype called IgM to an isotype called IgGs. To illustrate the effects of Fut8 in the class-switching of immunoglobulin, we measured the class-switched (IgGs of different subclasses) and non-switched (IgM) in the sera of Fut8+/+ and Fut8−/− mice using mouse mAb isotyping reagents. In 4-week-old Fut8−/− mice, the amounts of IgG1, IgG2a, IgG2b, and IgG3 were significantly lower than those in Fut8+/+ mice after OVA immunization, while those of IgM were relatively normal (Figure 3C). The cytokines, such as IL-4, IL-5, IL-6, and IFNγ secreted by CD4+ T cells, contribute to the different IgG class-switching in the mice and human. It is reasonable to consider that the reduced IgG class-switching attributed to the low levels of cytokines secreted by CD4+ T cells in Fut8−/− mice (Table 1). In addition, since the TGF receptor signaling was attenuated in the Fut8−/− mice (19), the IgG3 class-switching regulated by TGF signaling was also suppressed in the Fut8−/− mice.
Table 1.
Gene name | Gene access number | Fold change (Fut8+/+/Fut8−/−) |
---|---|---|
T-cell activation | ||
CD3e | NM-007648 | 2.15 |
CD4 | NM-013488 | 3.16 |
CD8 | NM-009858 | 2.51 |
Cd40L | NM-011616 | 2.17 |
IL-2Rα | NM-008367 | 3.04 |
IL-4 | NM-021283 | 2.18 |
IL-6 | NM-031168 | 2.14 |
IL-10 | NM-010548 | 2.25 |
IL-12 | NM-008352 | 3.89 |
IFNγ | NM-008337 | 3.08 |
CXCR4 | NM-009911 | 2.04 |
CXCL12 | NM-001012477 | 2.07 |
B-cell activation | ||
CD79a | NM-007655 | 3.35 |
CD81 | NM-133655 | 2.82 |
Cell signaling | ||
MAPKKK | NM_009316 | 2.41 |
Vav1 | NM-011691 | 3.28 |
PIK3 | NM-001077495 | 2.36 |
PKC | NM-008859 | 2.00 |
Cyclin D3 | NM-001081636 | 3.84 |
Loss of Core Fucosylation Impaired the Signal Transduction via TCR
T cell receptor signaling is very important for T cell activation. As illustrated in Figure 4A, no different expression of TCR was found in the Fut8+/+CD4+ T and Fut8−/−CD4+ T cells. Nonetheless, the core fucose of the N-glycans in the molecules was eliminated by a disruption of the Fut8 (Figure 4B). Moreover, the MS spectra of N-glycans released from TCRs were analyzed. It is notable that the high levels of signals were corresponded to the core-fucosylated glycans bearing non-, mono-, or di-galactose in the Fut8+/+CD4+ T cells, while those were completely disappeared in Fut8−/−CD4+ T cells (Figure S2 in Supplementary Material). These results further confirmed in mice that TCRs are highly core-fucosylated proteins and contributes to its activities.
In order to examine the role of core fucosylation in the activation of CD4+ T cells, we isolated CD4+ T cells from Fut8+/+ and Fut8−/− mice, and checked the level of core fucosylation. FACS analysis showed that core fucosylation on the cellular surfaces was abolished in Fut8−/− CD4+ T cells (Figure 4C). We compared the phosphorylation levels of Fut8+/+CD4+ T cells with Fut8−/−CD4+ T cells in response to costimulations with anti-CD3/CD28 Abs. In those comparisons, the levels of pZAP-70 in Fut8−/−CD4+ T cells were significantly lower than those in Fut8+/+CD4+ T cells (Figure 4D). Moreover, the populations of CD69+ cells (activated T cells) in Fut8−/−CD4+ T cells were lower than those in Fut8+/+CD4+ T cells following OVA immunization, while these were similar before immunization (Figure 4E). Furthermore, cell proliferation of Fut8−/−CD4+ T cells was significantly reduced in response to the stimulation of anti-CD3/CD28 Abs (Figure 4F).
Core Fucosylation Is Essential for TCR–pMHC Conjugates in CD4+ T Cell Activation
B cells present antigenic peptide with MHC-II molecule as APCs, and CD4+ T cells physiologically recognize a complex of a peptide-loaded MHC-II in T–B cell interaction (18). Therefore, we were interested in determining whether core fucosylation is involved in the TCR sensitivity to pMHC-II. To explore the role of core fucosylation on the TCR interaction with pMHC-II ligands, we crossed Fut8+/− mice with OT-II TCR transgenic mice (expressing CD4+ TCR specific for OVA323–339), and obtained Fut8+/+OT-II and Fut8−/−OT-II mice. LCA blots analysis showed that the core fucosylation level of T and B cells in Fut8−/−OT-II mice (Figure S3 in Supplementary Material). Since MHC-II on the B cell surface can present peptides for recognition and activation of T cells, in this study, B cells were isolated from Fut8+/+OT-II and Fut8−/−OT-II spleen and incubated with monobiotin-labeled OVA323–339. Although electron density was seen for the structures of I-Ad covalently linked to an OVA323–339, with a single N-glycan (24), the core fucosylation did not affect the peptide presentation abilities of the MHCs between Fut8+/+OT-II and Fut8−/−OT-II B cells (Figure S4 in Supplementary Material). The CD4+ T cells were then stimulated with OVA323–339 loaded B cells and subsequent T cell priming was investigated. The freshly purified ex vivo CD4+ T cells were stimulated with the OVA323–339-loaded B cells. As shown in Figure 5A, compared with Fut8+/+OT-II CD4+ T cells, the phosphorylation level of ZAP-70 was dramatically decreased in Fut8−/−OT-II CD4+ T cells with stimulation of OVA323–339-loaded B cells. Moreover, to remove the cell-surface fucosylation, the Fut8+/+OT-II CD4+ T cells were treated with 100 mU Glyko® α(1-2,3,4,6) Fucosidase, which can cleaves α1,6-linked fucose more efficiently than other α-fucose linkages (25). The signaling via TCR was significantly suppressed in OT-II CD4+ T cells treated with this fucosidase, when the T cells were stimulated with OVA323–339-loaded B cells (Figure 5B), indicated that the Fut8 inactivation results in the less responsive for TCR stimulation with pMHC-II, despite similar TCR expression levels (Figure 4A). Moreover, the population of TCR+CD69+ cells was significantly reduced in Fut8−/−OT-II CD4+ T/OVA323–339-loaded B cells compared with Fut8+/+OT-II CD4+ T/OVA323–339-loaded B cells (Figure 5C).
To further determine how Fut8 deficiency affects the T–B cell interactions, the communication of CD4+ T cells and B cells was observed by confocal microscopy. OVA323–339-loaded MHC-II was markedly increased at the site of T–B cell contact in Fut8+/+OT-II T cells for 30 min and was ubiquitous on the Fut8−/−OT-II T cell surface (Figures 5D,E). Next, T–B cell conjugates were quantitatively analyzed via flow cytometry analysis. Few conjugates of T–B cells were observed in the absence of OVA323–339 peptide, whereas peptide-pulsed B cells effectively interacted with CD4+ T cells. The percentages of T–B cell conjugates in Fut8+/+OT-II and Fut8−/−OT-II MHC-II+ TCRβ+ cells were 29.4 and 7.4%, respectively (Figures 5F,G), indicated that core fucosylation affected the T–B cell interaction. Moreover, the secretion of IL-2 was reduced in the culture media of Fut8−/−OT-II T–B cells compared with Fut8+/+OT-II T–B cells (Figure 5H). Furthermore, the T cell proliferation with OVA323–339-loaded B cells was analyzed by CFSE dilution methods. Compared to the proliferation of Fut8+/+OT-II CD4+ T cells, those of Fut8−/−OT-II CD4+ T cells was significantly reduced with the cocultivation of OVA323–339-loaded Fut8+/+OT-II B cells (Figure 5I). These results indicated that Fut8 deficiency contributes to attenuated T–B cell communication, and follows attenuated T cell activation.
To further elucidate the underlying mechanism of the reduced T–B cell interaction caused by the disruption of Fut8, T and B cell Activation PCR Array was used to compare mRNA expression in Fut8+/+ SPLs with that in Fut8−/− SPLs following OVA immunization. As illustrated in Table 1, the expression levels of four genes (CD3e, CD4, CD8, and CD40L) associated with TCR complex formation, eight genes (IL-2Rα, IL-4, IL-6, IL-10, IL-12, IFNγ, CXCL12, and CXCR4) involved in T cell activation, and two genes (CD79a and CD81) associated with B cell activation, were downregulated in Fut8−/− SPLs. Moreover, the gene expressions of signal molecules such as MAPKKK, Vav1, PIK3, PKC, and Cyclin D3 were downregulated in Fut8−/− SPLs. Since core fucosylation of proteins is an important post-translational process, it is not surprising that many molecules involved in T and B cell activation were downregulated in Fut8−/− SPLs.
Discussion
The glycosylation and Golgi processing pathways have coevolved with the larger regulatory network that controls T cell activation. It is not surprising that changes of glycosylation are linked to AD pathogenesis, such as galactosylation (26, 27) and sialylation (28, 29). The lower levels of sialylated IgG were found in rheumatoid arthritis (RA) and Wegener’s granulomatosis patients, and the sialylated IgG was increased in the sera of patients during remission (28, 29). Moreover, loss of galactose residues on IgG1 is showed in the sera of RA patients (26, 27). The significant differences of O-glycan on T helper cells were detected in active SLE patients (30). Core-fucosylated glycans that contain bisecting GlcNAc was increased on the IgG of SLE (31). In this study, core fucosylations were associated with SLE severities, and significantly increased in the CD4+ T cells of SLE patients. Coincidently, previous study by Fujii et al. found that the core fucosylation on T cells, required for activation of TCR signaling with anti-CD3/CD28 Abs and induction in colitis, is significantly increased in patients with inflammatory bowel disease (32). Hence, one possible consequence of hyper core fucosylation-induced T cell activation could be the development of SLE. However, the underlying mechanisms of how core fucosylation regulate T cell activation with TCR–pMHC interaction remain unclear.
T cell recognition of pMHC-II ligands on B cells is thought to be carefully coordinated in CD4+ T cells. Conformational flexibility is likely responsible for the high degree of promiscuity or cross-reactivity that is evident in the TCR recognition of pMHCs (33–35). There are two models to explain how TCR–pMHC interactions result in T cell activation (36, 37). One model involves an activation threshold based on the occupancy time of the TCR clustering with pMHCs. The alternative model is that pMHC could induce a specific conformational change of TCR complex and influence the quality of signal transductions via TCRs. Since the core fucose of N-glycan is located on the cellular surface of T and B cells, and the core fucosylation could affect the flexibility of N-glycan antenna (38) as well as the conformational stability of proteins (39), it is reasonable to assume that core fucosylation of TCR would affect the geometry and conformation of any TCR–pMHC clusters in the T–B cell interactions. Based on a previous study in D. melanogaster cells, the closeness of the interaction of Cα with Cβ is shown by the hydrogen bonds of the core fucose residue (6, 17), suggested core fucose possibly strengthens association of Cα with Cβ. A water molecule also bridges the fucose exocyclic oxygen and the side chain of Arg150β (17). In this scenario, core fucosylation is expected to provide exciting opportunities to control the TCR function. In the present study, the percentage of T–B cell conjugates (TCR+MHC-II+) was reduced by a factor of 3.97 (29.4/7.4%) in Fut8−/−OT-II cells, indicated that the core fucosylation has significant functional implications in TCR–pMHC interaction.
Given the intimate relationship between pMHC recognition and TCR signaling, the signaling via TCR is also be regulated by glycosylation. It has long been appreciated that Mgat5 deficiency could enhance TCR recruitment to the synapse and results in greater TCR internalization/endocytosis (11). Physiologically, TCR recognition of pMHC-II ligands on APCs such as dendritic cells and B cells are the most important checkpoint for CD4+ T cell activation (40). Engagement of the TCR complexes leads to a signaling cascade of protein tyrosine kinases, such as ZAP70. To explore the role of core fucosylation on the T cell activation, we generated Fut8+/+OT-II and Fut8−/−OT-II mice. Fut8 deficiency results in the attenuated phosphorylation of ZAP70 in Fut8−/−OT-II CD4+ T cells with OVA323–339-loaded B cells. Also, the phosphorylation of ZAP-70 was significantly reduced in Fut8+/+OT-II CD4+ T cells by the treatment of fucosidase. Moreover, in Fut8−/−OT-II cells, the number of CD4+ T cells activation (CD69+) was decreased by a factor of 3.5. The proliferation of the Fut8−/−OT-II CD4+ T cells cocultivated with OVA323–339-loaded B cells was decreased compared with the Fut8+/+OT-II CD4+ T cells. It is conceivable that low T–B cell conjugates was proportional to the decreased T cell activation and proliferation in Fut8−/− CD4+ T cells. Core fucosylation is likely to be important in all three proposed stages involved in the T cell activation. First, core fucosylation is essential for the TCR structural formation. Second, core fucosylation of TCR could regulate the recognition of pMHC and affect T cell activation threshold. Third, fucose-specific lectins (41) might participate the events in the T–B cell interaction.
Systemic lupus erythematosus is characterized by the overproduction of auto antibodies, mainly IgG. However, B lymphocyte hyperactivity in SLE is T cell dependent. T cells from SLE patients are activated with a decreased activation threshold and regulated abnormally (32). Indeed, overactive CD4+ T cells had been implicated in the pathogenesis of SLE (42). Although we know that CD4+ T cell deregulation contributes to SLE pathogenesis, but the mechanism is still largely unknown. Studies in SLE patients and murine models of lupus have shown enhanced level of IL-4 (43), IFNγ (44), and IL-6 (45, 46). Compared to Fut8+/+ mice, the IgG class-switching was significantly reduced in the sera of Fut8−/− mice after OVA immunization due to low levels of IL-4, IL-5, IL-6, IFNγ, and TGF secreted by Fut8−/−CD4+ T cells. Development of SLE is associated with genetic, hormonal, environmental, and immunological factors, mainly those related to the helper T cell activation. To investigate the mechanisms of the CD4+ T cell activation that is important for SLE pathogenesis, we induced the EAE model using Fut8+/+ and Fut8−/− mice. Loss of Fut8 reduced CD4+ T cell activation and ameliorated the EAE in Fut8−/− mice. Fut8−/− mice are resistant to the induction of EAE, whereas Mgat5−/− mice are hypersensitive to it (47). In this regard, Fut8 and Mgat5 function as opposing regulators of T cell activation thresholds and susceptibility to AD. The hyper core fucosylations are associated with SLE severities, however, whether altered core fucosylation is a consequence or an underlying cause of the SLE cascade remains unclear.
FUT8 is able to modify multiple proteins, followed by the change of their functions. Because the most of immune response molecules are glycoproteins, FUT8 knockdown/knock out affected their function associated with immune response. Okada et al. (10) showed that loss of core fucosylation caused an inhibitory receptor PD-1 deprivation on the cellular surface and augmented T cell activation, when Fut8−/−CD4+ T cells transferred into Rag2−/− mice. Although we did not measure the cell-surface PD-1 expression in the T cell activation and T–B cell interaction, the core fucosylation could regulate the PD-1 expression by modulating TCR signaling strength. Physiologically, there may be some equilibria of the core fucosylation on the TCR and PD-1 to regulate T cell activation. The complexity of in vivo condition made us cannot conclude the inability for TCR signaling pathway is the sole reason for the T cell activation, but our study first revealed that Fut8 is essential for TCR–pMHC contact and the following CD4+ T cell activation. The balance between specific and degenerate T cell recognition of pMHC-II holds important implications for protective immunity versus autoimmunity. With a better understanding of how core fucosylation regulates of the adaptive immune system, its use in therapy for SLE may prove to be a useful intervention.
Ethics Statement
All animal work was approved by the Ethics Committee at the Dalian Medical University. The Ethics Committee at the hospital approved the study protocol.
Author Contributions
WL, SM, and SS designed research and performed experiment; ML, ZL, and RY analyzed the experimental data; TM, JG, JZ, and NT corrected paper; WL designed research and wrote paper. All authors reviewed the results and approved the final version of the manuscript.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Footnotes
Funding. This work was supported by the National Nature Science Foundation of China (31570797, 31270864, 30972675), and Natural Science Foundation of Liaoning Province (2015020253), China.
Supplementary Material
The Supplementary Material for this article can be found online at http://www.frontiersin.org/articles/10.3389/fimmu.2018.00078/full#supplementary-material.
References
- 1.Yin Y, Choi SC, Xu Z, Perry DJ, Seay H, Croker BP, et al. Normalization of CD4+ T cell metabolism reverses lupus. Sci Transl Med (2015) 7(274):274ra18. 10.1126/scitranslmed.aaa0835 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Rupanagudi KV, Kulkarni OP, Lichtnekert J, Darisipudi MN, Mulay SR, Schott B, et al. Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming. Ann Rheum Dis (2015) 74(2):452–63. 10.1136/annrheumdis-2013-203717 [DOI] [PubMed] [Google Scholar]
- 3.Reinherz EL, Tan K, Tang L, Kern P, Liu J, Xiong Y, et al. The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science (1999) 286(5446):1913–21. 10.1126/science.286.5446.1913 [DOI] [PubMed] [Google Scholar]
- 4.Lee KH, Holdorf AD, Dustin ML, Chan AC, Allen PM, Shaw AS. T cell receptor signaling precedes immunological synapse formation. Science (2002) 295(5559):1539–42. 10.1126/science.1067710 [DOI] [PubMed] [Google Scholar]
- 5.Johnson JL, Jones MB, Ryan SO, Cobb BA. The regulatory power of glycans and their binding partners in immunity. Trends Immunol (2013) 34(6):290–8. 10.1016/j.it.2013.01.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Rudd PM, Wormald MR, Stanfield RL, Huang M, Mattsson N, Speir JA, et al. Roles for glycosylation of cell surface receptors involved in cellular immune recognition. J Mol Biol (1999) 293(2):351–66. 10.1006/jmbi.1999.3104 [DOI] [PubMed] [Google Scholar]
- 7.Daniels MA, Hogquist KA, Jameson SC. Sweet ‘n’ sour: the impact of differential glycosylation on T cell responses. Nat Immunol (2002) 3(10):903–10. 10.1038/ni1002-903 [DOI] [PubMed] [Google Scholar]
- 8.Lowe JB. Glycosylation, immunity, and autoimmunity. Cell (2001) 104(6):809–12. 10.1016/S0092-8674(01)00277-X [DOI] [PubMed] [Google Scholar]
- 9.Rudd PM, Elliott T, Cresswell P, Wilson IA, Dwek RA. Glycosylation and the immune system. Science (2001) 291(5512):2370–6. 10.1126/science.291.5512.2370 [DOI] [PubMed] [Google Scholar]
- 10.Okada M, Chikuma S, Kondo T, Hibino S, Machiyama H, Yokosuka T, et al. Blockage of core fucosylation reduces cell-surface expression of PD-1 and promotes anti-tumor immune responses of T cells. Cell Rep (2017) 20(5):1017–28. 10.1016/j.celrep.2017.07.027 [DOI] [PubMed] [Google Scholar]
- 11.Demetriou M, Granovsky M, Quaggin S, Dennis JW. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature (2001) 409(6821):733–9. 10.1038/35055582 [DOI] [PubMed] [Google Scholar]
- 12.Lau KS, Partridge EA, Grigorian A, Silvescu CI, Reinhold VN, Demetriou M, et al. Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell (2007) 129(1):123–34. 10.1016/j.cell.2007.01.049 [DOI] [PubMed] [Google Scholar]
- 13.Starr TK, Daniels MA, Lucido MM, Jameson SC, Hogquist KA. Thymocyte sensitivity and supramolecular activation cluster formation are developmentally regulated: a partial role for sialylation. J Immunol (2003) 171(9):4512–20. 10.4049/jimmunol.171.9.4512 [DOI] [PubMed] [Google Scholar]
- 14.Moore GT, Brown SJ, Winterhalter AC, Lust M, Salvaris EJ, Selan C, et al. Glycosylation changes in hFUT1 transgenic mice increase TCR signaling and apoptosis resulting in thymocyte maturation arrest. Mol Immunol (2008) 45(8):2401–10. 10.1016/j.molimm.2007.11.006 [DOI] [PubMed] [Google Scholar]
- 15.Kuball J, Hauptrock B, Malina V, Antunes E, Voss RH, Wolfl M, et al. Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain. J Exp Med (2009) 206(2):463–75. 10.1084/jem.20082487 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Calderon AD, Liu Y, Li X, Wang X, Chen X, Li L, et al. Substrate specificity of FUT8 and chemoenzymatic synthesis of core-fucosylated asymmetric N-glycans. Org Biomol Chem (2016) 14(17):4027–31. 10.1039/c6ob00586a [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Garcia KC, Degano M, Stanfield RL, Brunmark A, Jackson MR, Peterson PA, et al. An alphabeta T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex. Science (1996) 274(5285):209–19. 10.1126/science.274.5285.209 [DOI] [PubMed] [Google Scholar]
- 18.Batista FD, Harwood NE. The who, how and where of antigen presentation to B cells. Nat Rev Immunol (2009) 9(1):15–27. 10.1038/nri2454 [DOI] [PubMed] [Google Scholar]
- 19.Wang X, Inoue S, Gu J, Miyoshi E, Noda K, Li W, et al. Dysregulation of TGF-beta1 receptor activation leads to abnormal lung development and emphysema-like phenotype in core fucose-deficient mice. Proc Natl Acad Sci U S A (2005) 102(44):15791–6. 10.1073/pnas.0507375102 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Uozumi N, Teshima T, Yamamoto T, Nishikawa A, Gao YE, Miyoshi E, et al. A fluorescent assay method for GDP-L-Fuc:N-acetyl-beta-D-glucosaminide alpha 1-6fucosyltransferase activity, involving high performance liquid chromatography. J Biochem (1996) 120(2):385–92. 10.1093/oxfordjournals.jbchem.a021424 [DOI] [PubMed] [Google Scholar]
- 21.Watson AR, Lee WT. Differences in signaling molecule organization between naive and memory CD4+ T lymphocytes. J Immunol (2004) 173(1):33–41. 10.4049/jimmunol.173.1.33 [DOI] [PubMed] [Google Scholar]
- 22.Tateno H, Nakamura-Tsuruta S, Hirabayashi J. Comparative analysis of core-fucose-binding lectins from Lens culinaris and Pisum sativum using frontal affinity chromatography. Glycobiology (2009) 19(5):527–36. 10.1093/glycob/cwp016 [DOI] [PubMed] [Google Scholar]
- 23.Mao L, Hou H, Wu S, Zhou Y, Wang J, Yu J, et al. TIGIT signalling pathway negatively regulates CD4+ T-cell responses in systemic lupus erythematosus. Immunology (2017) 151(3):280–90. 10.1111/imm.12715 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Scott CA, Peterson PA, Teyton L, Wilson IA. Crystal structures of two I-Ad-peptide complexes reveal that high affinity can be achieved without large anchor residues. Immunity (1998) 8(3):319–29. 10.1016/S1074-7613(00)80537-3 [DOI] [PubMed] [Google Scholar]
- 25.O’Flaherty R, Harbison AM, Hanley PJ, Taron CH, Fadda E, Rudd PM. Aminoquinoline fluorescent labels obstruct efficient removal of N-glycan core alpha(1-6) fucose by bovine kidney alpha-l-fucosidase (BKF). J Proteome Res (2017) 16(11):4237–43. 10.1021/acs.jproteome.7b00580 [DOI] [PubMed] [Google Scholar]
- 26.Parekh RB, Roitt IM, Isenberg DA, Dwek RA, Ansell BM, Rademacher TW. Galactosylation of IgG associated oligosaccharides: reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity. Lancet (1988) 1(8592):966–9. 10.1016/S0140-6736(88)91781-3 [DOI] [PubMed] [Google Scholar]
- 27.Ercan A, Cui J, Chatterton DE, Deane KD, Hazen MM, Brintnell W, et al. Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum (2010) 62(8):2239–48. 10.1002/art.27533 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Matsumoto A, Shikata K, Takeuchi F, Kojima N, Mizuochi T. Autoantibody activity of IgG rheumatoid factor increases with decreasing levels of galactosylation and sialylation. J Biochem (2000) 128(4):621–8. 10.1093/oxfordjournals.jbchem.a022794 [DOI] [PubMed] [Google Scholar]
- 29.Espy C, Morelle W, Kavian N, Grange P, Goulvestre C, Viallon V, et al. Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener’s). Arthritis Rheum (2011) 63(7):2105–15. 10.1002/art.30362 [DOI] [PubMed] [Google Scholar]
- 30.Ramos-Martinez E, Lascurain R, Tenorio EP, Sanchez-Gonzalez A, Chavez-Rueda K, Chavez-Sanchez L, et al. Differential expression of O-glycans in CD4(+) T lymphocytes from patients with systemic lupus erythematosus. Tohoku J Exp Med (2016) 240(1):79–89. 10.1620/tjem.240.79 [DOI] [PubMed] [Google Scholar]
- 31.Vuckovic F, Kristic J, Gudelj I, Teruel M, Keser T, Pezer M, et al. Association of systemic lupus erythematosus with decreased immunosuppressive potential of the IgG glycome. Arthritis Rheumatol (2015) 67(11):2978–89. 10.1002/art.39273 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Fujii H, Shinzaki S, Iijima H, Wakamatsu K, Iwamoto C, Sobajima T, et al. Core fucosylation on T cells, required for activation of T-cell receptor signaling and induction of colitis in mice, is increased in patients with inflammatory bowel disease. Gastroenterology (2016) 150(7):1620–32. 10.1053/j.gastro.2016.03.002 [DOI] [PubMed] [Google Scholar]
- 33.Alarcon B, Gil D, Delgado P, Schamel WW. Initiation of TCR signaling: regulation within CD3 dimers. Immunol Rev (2003) 191:38–46. 10.1034/j.1600-065X.2003.00017.x [DOI] [PubMed] [Google Scholar]
- 34.Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today (1998) 19(9):395–404. 10.1016/S0167-5699(98)01299-7 [DOI] [PubMed] [Google Scholar]
- 35.Kass I, Buckle AM, Borg NA. Understanding the structural dynamics of TCR-pMHC complex interactions. Trends Immunol (2014) 35(12):604–12. 10.1016/j.it.2014.10.005 [DOI] [PubMed] [Google Scholar]
- 36.Alam SM, Davies GM, Lin CM, Zal T, Nasholds W, Jameson SC, et al. Qualitative and quantitative differences in T cell receptor binding of agonist and antagonist ligands. Immunity (1999) 10(2):227–37. 10.1016/S1074-7613(00)80023-0 [DOI] [PubMed] [Google Scholar]
- 37.Schamel WW, Arechaga I, Risueno RM, van Santen HM, Cabezas P, Risco C, et al. Coexistence of multivalent and monovalent TCRs explains high sensitivity and wide range of response. J Exp Med (2005) 202(4):493–503. 10.1084/jem.20042155 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Stubbs HJ, Lih JJ, Gustafson TL, Rice KG. Influence of core fucosylation on the flexibility of a biantennary N-linked oligosaccharide. Biochemistry (1996) 35(3):937–47. 10.1021/bi9513719 [DOI] [PubMed] [Google Scholar]
- 39.Wormald MR, Dwek RA. Glycoproteins: glycan presentation and protein-fold stability. Structure (1999) 7(7):R155–60. 10.1016/S0969-2126(99)80095-1 [DOI] [PubMed] [Google Scholar]
- 40.Wolfert MA, Boons GJ. Adaptive immune activation: glycosylation does matter. Nat Chem Biol (2013) 9(12):776–84. 10.1038/nchembio.1403 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Lehrman MA, Hill RL. The binding of fucose-containing glycoproteins by hepatic lectins. Purification of a fucose-binding lectin from rat liver. J Biol Chem (1986) 261(16):7419–25. [PubMed] [Google Scholar]
- 42.Moulton VR, Tsokos GC. T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity. J Clin Invest (2015) 125(6):2220–7. 10.1172/jci78087 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Mi XB, Zeng FQ. Hypomethylation of interleukin-4 and -6 promoters in T cells from systemic lupus erythematosus patients. Acta Pharmacol Sin (2008) 29(1):105–12. 10.1111/j.1745-7254.2008.00739.x [DOI] [PubMed] [Google Scholar]
- 44.Gerez L, Shkolnik T, Hirschmann O, Lorber M, Arad G, Kaempfer R. Hyperinducible expression of the interferon-gamma (IFN-gamma) gene and its suppression in systemic lupus erythematosus (SLE). Clin Exp Immunol (1997) 109(2):296–303. 10.1046/j.1365-2249.1997.4471345.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol (1991) 147(1):117–23. [PubMed] [Google Scholar]
- 46.Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Klareskog L, Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol (2000) 18(5):565–70. [PubMed] [Google Scholar]
- 47.Grigorian A, Lee SU, Tian W, Chen IJ, Gao G, Mendelsohn R, et al. Control of T cell-mediated autoimmunity by metabolite flux to N-glycan biosynthesis. J Biol Chem (2007) 282(27):20027–35. 10.1074/jbc.M701890200 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.